Transcatheter arterial chemoembolization alone versus combined with microwave ablation for recurrent small hepatocellular carcinoma after resection: a retrospective comparative study

Purpose To compare the efficacy and safety of transcatheter arterial chemoembolization combined with microwave ablation (TACE-MWA) versus TACE alone for the treatment of recurrent small hepatocellular carcinoma (sHCC) after resection. Materials and methods From June 2015 to January 2020, a total of...

Full description

Saved in:
Bibliographic Details
Published in:BMC gastroenterology 2022-06, Vol.22 (1), p.1-321, Article 321
Main Authors: Ji, Jie, Yang, Wei, Shi, Hai-Bin, Liu, Sheng, Zhou, Wei-Zhong
Format: Article
Language:English
Subjects:
Ablation
Cancer
Care and treatment
Catheters
Chemoembolization
Chemotherapy
Combined modality therapy
Comparative analysis
Gastroenterology
Hepatectomy
Hepatocellular carcinoma
Hepatoma
Liver cancer
Medical prognosis
Methods
Microwave ablation
Oncology, Experimental
Patient outcomes
Patients
Recurrence
Relapse
Small hepatocellular carcinoma
Solid tumors
Survival
Therapeutic chemoembolization
Transcatheter arterial chemoembolization
Tumors
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To compare the efficacy and safety of transcatheter arterial chemoembolization combined with microwave ablation (TACE-MWA) versus TACE alone for the treatment of recurrent small hepatocellular carcinoma (sHCC) after resection. Materials and methods From June 2015 to January 2020, a total of 45 patients with recurrent sHCC (size [less than or equai to] 3 cm) treated by TACE-MWA or TACE were included in this study. The radiological response at 1-, 3-, 6-month after initial treatment [modified Response Evaluation Criteria in Solid Tumors (mRECIST)], progression-free survival (PFS), overall survival (OS), and complications were evaluated. Results The TACE-MWA group showed better 1-, 3-, 6-month tumor response rates than TACE group. The corresponding 1-, 3-, and 5-year PFS rates were 76.5%, 70.6%, and 70.6% for the TACE-MWA group, and 56.1%, 15.0%, and 15.0% for the TACE group (P = 0.003). The 1-, 3-, and 5-year OS rates were 100.0%, 82.1%, and 61.5% for the TACE-MWA group, and 89.0%, 58.1%, and 50.8% for the TACE group (P = 0.389), respectively. Moreover, no major complications related to treatment were observed in either of the groups. Compared with the TACE group, the TACE-MWA group had a significantly lower number of re-TACE sessions (P = 0.003). Conclusions Although TACE alone provides equivalent effectiveness for recurrent sHCC in terms of OS rates, TACE-MWA had better 1-, 3-, 6-month tumor response rates and may prolong tumor PFS time. Keywords: Recurrence, Small hepatocellular carcinoma, Microwave ablation, Transcatheter arterial chemoembolization
ISSN:1471-230X
1471-230X
DOI:10.1186/s12876-022-02387-7